Monitoring report on US GLP-1 RA prescribing trends shows increased oral semaglutide use.
Why are so many people getting new diabetes and weight-loss drugs?
This monitoring report analyzes real-world US electronic health record data from Truveta on GLP-1 RA prescribing. It finds increased prescri…
Prescriptions for diabetes and weight-loss drugs jumped sharply in the US after a new oral pill was approved, with first-time use rising ove…
Observational study links semaglutide dose and weight loss to lower liver disease risk.
Study links semaglutide use to lower risk of several liver conditions in patients with liver disease
This observational study from a real-world federated EHR network analyzed 6,734 patients with liver disease. It found associations between h…
Higher semaglutide doses and greater weight loss were linked to lower risks of steatohepatitis, alcoholic liver disease, and death in patien…
Tirzepatide shows greater lean body mass loss than semaglutide in first-episode GLP-1RA users with type 2 diabetes
One Weight-Loss Drug Trims More Muscle Than the Other — Here's Why
An observational study of 670,422 first-episode GLP-1RA users with type 2 diabetes found tirzepatide was associated with greater relative le…
Losing weight with a popular injection drug is not all equal — one drug may chip away at your muscle more than the other, which matters grea…
Orforglipron shows superior HbA1c reduction versus oral semaglutide in adults with type 2 diabetes on metformin
A New Diabetes Pill Takes On Ozempic's Oral Cousin
A phase 3 RCT of 1698 adults with type 2 diabetes inadequately controlled on metformin found that once-daily oral orforglipron (12 mg or 36 …
A new once-daily diabetes pill called orforglipron lowered blood sugar better than oral semaglutide in a major head-to-head trial, but at th…
Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD
Why Ozempic's Heart Benefits May Have Nothing to Do With Weight Loss
An observational study of 47,199 patients with baseline cardiovascular disease in a U.S. EHR network found higher maximum semaglutide dose w…
A massive real-world study of over 47,000 heart patients suggests that semaglutide may protect the heart through direct biological effects —…
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes.
A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…
Oral semaglutide reduces composite heart failure outcomes in patients with type 2 diabetes and heart failure history.
A Common Diabetes Pill May Also Protect Your Heart From Failure
This secondary analysis of a phase 3b randomized clinical trial evaluated once-daily oral semaglutide versus placebo in 9,650 participants w…
For millions living with type 2 diabetes and a struggling heart, a medication they might already be taking could offer a powerful, two-in-on…
Efruxifermin shows superior fibrosis regression in compensated MASH cirrhosis compared to placebo in a network meta-analysis.
New drug ranking shows one treatment stands out for advanced fatty liver scarring
This network meta-analysis evaluated histological efficacy in patients with biopsy-proven compensated metabolic dysfunction-associated steat…
Efruxifermin is the only drug proven to shrink advanced liver scarring without worsening the disease, ranking first among new treatments for…
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
Do heart benefits from diabetes drugs work equally well across different races?
A meta-analysis of 74,703 adults with type 2 diabetes or overweight/obesity found GLP-1RAs reduced MACE risk versus placebo. The reduction w…
Diabetes drugs protect hearts in Asian and White adults, but the benefit for Black adults remains unclear due to small study numbers.
Phase 1b trial of oral GLP-1 agonist HDM1002 shows weight reduction in Chinese adults with overweight/obesity
Can a new pill help with weight loss? Early trial shows promise.
A phase 1b randomized controlled trial in Chinese adults with overweight/obesity without diabetes found greater weight reductions with oral …
A new oral weight-loss pill helped adults lose about 6 kilograms in just 28 days, showing early promise compared to a placebo.
GLP-1 receptor agonists associated with lower respiratory sequelae risk in case report analysis
Could diabetes drugs help protect lungs? A new analysis of patient stories suggests a link.
An analysis of 136 single-patient case reports from PubMed Open Access found that GLP-1 receptor agonist users had a lower risk of respirato…
Diabetes drugs linked to lower risk of serious lung problems in a new look at patient stories.
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF.
New drugs may lower heart failure risk and improve walking distance for patients with preserved ejection fraction
This network meta-analysis evaluated 48,235 patients with heart failure with preserved ejection fraction (HFpEF) treated with various pharma…
New heart drugs lower death risk and hospital visits for patients with preserved ejection fraction while improving walking distance.